Dietary fructose induces endotoxemia and hepatic injury in calorically controlled primates

Kylie Kavanagh, Ashley T Wylie, Kelly L Tucker, Timothy J Hamp, Raad Z Gharaibeh, Anthony A Fodor, John M Cullen Cullen, Kylie Kavanagh, Ashley T Wylie, Kelly L Tucker, Timothy J Hamp, Raad Z Gharaibeh, Anthony A Fodor, John M Cullen Cullen

Abstract

Background: Controversy exists regarding the causative role of dietary fructose in obesity and fatty liver diseases. Clinical trials have indicated that negative health consequences may occur only when fructose is consumed within excess calories. Animal studies have suggested that fructose impairs intestinal integrity and leads to hepatic steatosis (HS).

Objectives: We assessed nonhuman primates after chronic ad libitum and short-term calorically controlled consumption of a high-fructose (HFr), low-fat diet (24% of calories). Microbial translocation (MT), microbiome, and metabolic health indexes were evaluated.

Design: Seventeen monkeys fed 0.3–7 y of an HFr ad libitum diet were compared with 10 monkeys fed a low-fructose, low-fat diet (control). Ten middle-aged, weight-stable, fructose-naive monkeys were stratified into HFr and control groups fed for 6 wk at caloric amounts required to maintain weight stability. Metabolic endpoints, feces, liver, small and large intestinal biopsies, and portal blood samples were collected.

Results: Monkeys allowed ad libitum HFr developed HS in contrast to the control diet, and the extent of ectopic fat was related to the duration of feeding. Diabetes incidence also increased. Monkeys that consumed calorically controlled HFr showed significant increases in biomarkers of liver damage, endotoxemia, and MT indexes and a trend for greater hepatitis that was related to MT; however, HS did not develop.

Conclusions: Even in the absence of weight gain, fructose rapidly causes liver damage that we suggest is secondary to endotoxemia and MT. HS relates to the duration of fructose consumption and total calories consumed. These data support fructose inducing both MT and ectopic fat deposition in primates.

Figures

FIGURE 1.
FIGURE 1.
A: Least-squares mean (±SEM) hepatic steatosis scores adjusted for diet duration, age, and body weight. Scores were calculated from a histologic section examination by duplicate blind reviewers from monkeys fed an ad libitum CTL (n = 10) or HFr (n = 17). The HFr induced greater liver fat deposition (ANCOVA; *P < 0.001). B: Scatterplot of hepatic steatosis scores and duration of consumption of either the CTL (n = 10; open circles) or HFr (n = 17; closed circles). The partial correlation coefficient reflects adjustment for age and body weight (r = 0.61, P < 0.05). Monkeys that ate the CTL had lifelong exposure but are represented at 0.2 y, which reflects the time that they were housed at the same site as HFr monkeys. The majority of these CTL monkey values are superimposed with a steatosis score of 0, and thus, the 10 animals are not discriminated on the graph. CTL, low-fat, low-fructose diet; HFr, low-fat, high-fructose diet.
FIGURE 2.
FIGURE 2.
A: Mean (±SEM) scores for liver pathology as assessed by histologic grading for inflammation from monkeys fed either a CTL (n = 5) or HFr (n = 5) for 6 wk. An ANCOVA P value is shown. B: Representative histologic section from a monkey fed the HFr (histologic score: 3) showing the periportal inflammatory infiltrate seen in fructose-fed monkeys. C: Representative histologic section from a liver biopsy taken from a CTL monkey (histologic score: 0). CTL, low-fat, low-fructose diet; HFr, low-fat, high-fructose diet.
FIGURE 3.
FIGURE 3.
Representative liver histologic sections stained for lipid with oil red O. Low-fat, high fructose–fed monkeys (A) had similar lipid amounts quantified by histology and direct biochemical analysis as did low-fat, low-fructose–fed monkeys (B) (4.66% compared with 3.48% by area, respectively; ANCOVA P = 0.38).
FIGURE 4.
FIGURE 4.
A: Endotoxin concentrations representing microbial translocation were measured from portal plasma samples taken after 6-wk consumption of controlled intakes of either a CTL (n = 5) or HFr (n = 5). *ANCOVA P = 0.05. B: The ligand for LPS (sCD14) significantly increased in the peripheral circulation after only 6 wk in monkeys fed the HFr. *ANCOVA P = 0.02. C: The binding protein for LPS (LBP-1) significantly increased in the peripheral circulation after only 6 wk in monkeys fed the HFr. *ANCOVA P = 0.04. CTL, low-fat, low-fructose diet; HFr, low-fat, high-fructose diet; LBP-1, LPS binding protein-1; sCD14, soluble CD14.
FIGURE 5.
FIGURE 5.
Cluster diagram on the basis of a PCoA of the fecal microbiome. Animal identification numbers are shown on the graph. A: No differences were observed between monkeys fed the CTL (triangles; n = 5) and those fed the HFr (squares; n = 5) at baseline (P = 0.89 for PCoA 1 and P = 0.91 for PCoA 2). B: No differences were also observed at the study end (P = 0.92 for PCoA 1 and P = 0.48 for PCoA 2). CTL, low-fat, low-fructose diet; HFr, low-fat, high-fructose diet; PCoA, principal coordinate analysis.

References

    1. Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008;31:1138–43.
    1. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:15430–5.
    1. Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 2010;33:2477–83.
    1. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008;49:600–7.
    1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341–50.
    1. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155–61.
    1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–31.
    1. Sievenpiper JL, de Souza RJ, Mirrahimi A, Yu ME, Carleton AJ, Beyene J, Chiavaroli L, Di Buono M, Jenkins AL, Leiter LA, et al. Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med 2012;156:291–304.
    1. Coate KC, Scott M, Farmer B, Moore MC, Smith M, Roop J, Neal DW, Williams P, Cherrington AD. Chronic consumption of a high-fat/high-fructose diet renders the liver incapable of net hepatic glucose uptake. Am J Physiol Endocrinol Metab 2010;299:E887–98.
    1. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010;52:934–44.
    1. Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008;22:811–6.
    1. Kavanagh K, Fairbanks LA, Bailey JN, Jorgensen MJ, Wilson M, Zhang L, Rudel LL, Wagner JD. Characterization and heritability of obesity and associated risk factors in vervet monkeys. Obesity (Silver Spring) 2007;15:1666–74.
    1. Balzan S, de Almeida Quadros C, de Cleva R, Zilberstein B, Cecconello I. Bacterial translocation: overview of mechanisms and clinical impact. J Gastroenterol Hepatol 2007;22:464–71.
    1. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470–81.
    1. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Mace K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416–26.
    1. Riordan SM, McIver CJ, Williams R. Liver damage in human small intestinal bacterial overgrowth. Am J Gastroenterol 1998;93:234–7.
    1. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011;140:976–86.
    1. Pappo I, Becovier H, Berry EM, Freund HR. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 1991;51:106–12.
    1. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983–92.
    1. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3:559–72.
    1. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011;108(suppl 1):4586–91.
    1. Kavanagh K, Jones KL, Sawyer J, Kelley K, Carr JJ, Wagner JD, Rudel LL. Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity (Silver Spring) 2007;15:1675–84.
    1. Kavanagh K, Davis MA, Zhang L, Wilson MD, Register TC, Adams MR, Rudel LL, Wagner JD. Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. Arterioscler Thromb Vasc Biol 2009;29:1471–7.
    1. Bremer AA, Stanhope KL, Graham JL, Cummings BP, Wang W, Saville BR, Havel PJ. Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci 2011;4:243–52.
    1. Kritchevsky D, Davidson LM, Kim HK, Krendel DA, Malhotra S, Mendelsohn D, van der Watt JJ, duPlessis JP, Winter PA. Influence of type of carbohydrate on atherosclerosis in baboons fed semipurified diets plus 0.1% cholesterol. Am J Clin Nutr 1980;33:1869–87.
    1. Mubiru JN, Garcia-Forey M, Higgins PB, Hemmat P, Cavazos NE, Dick EJ, Jr, Owston MA, Bauer CA, Shade RE, Comuzzie AG, et al. A preliminary report on the feeding of cynomolgus monkeys (Macaca fascicularis) with a high-sugar high-fat diet for 33 weeks. J Med Primatol 2011;40:335–41.
    1. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23:203–8.
    1. Cozma AI, Sievenpiper JL, de Souza RJ, Chiavaroli L, Ha V, Wang DD, Mirrahimi A, Yu ME, Carleton AJ, Di Buono M, et al. Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials. Diabetes Care 2012;35:1611–20.
    1. Bravo S, Lowndes J, Sinnett S, Yu Z, Rippe J. Consumption of sucrose and high fructose corn syrup does not increase liver fat or ectopic fat in muscles. Appl Physiol Nutr Metab (in press).
    1. Beck-Nielsen H, Pedersen O, Lindskov HO. Impaired cellular insulin binding and insulin sensitivity induced by high-fructose feeding in normal subjects. Am J Clin Nutr 1980;33:273–8.
    1. Hallfrisch J, Ellwood KC, Michaelis OEt, Reiser S, O'Dorisio TM, Prather ES. Effects of dietary fructose on plasma glucose and hormone responses in normal and hyperinsulinemic men. J Nutr 1983;113:1819–26.
    1. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009;119:1322–34.
    1. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr 2009;139:1228S–35S.
    1. Bremer AA, Auinger P, Byrd RS. Sugar-sweetened beverage intake trends in US adolescents and their association with insulin resistance-related parameters. J Nutr Metab 2010;2010:196476..
    1. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961–71.
    1. Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest 2012;92:1020–32.
    1. Volynets V, Spruss A, Kanuri G, Wagnerberger S, Bischoff SC, Bergheim I. Protective effect of bile acids on the onset of fructose-induced hepatic steatosis in mice. J Lipid Res 2010;51:3414–24.
    1. Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, Bergheim I. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr 2012;107:1727–38.
    1. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, Chamontin B, Ferrieres J. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008;87:1219–23.
    1. Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, Salvador J, Ricart W, Fruhbeck G, Burcelin R, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012;36:1442–9.
    1. Huang S, Rutkowsky JM, Snodgrass RG, Ono-Moore KD, Schneider DA, Newman JW, Adams SH, Hwang DH. Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res 2012;53:2002–13.
    1. Trevisi P, De Filippi S, Minieri L, Mazzoni M, Modesto M, Biavati B, Bosi P. Effect of fructo-oligosaccharides and different doses of Bifidobacterium animalis in a weaning diet on bacterial translocation and Toll-like receptor gene expression in pigs. Nutrition 2008;24:1023–9.
    1. Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009;50:1094–104.
    1. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister EM, Wheeler MB, Adeli K. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 2009;297:E462–73.
    1. Payne AN, Chassard C, Lacroix C. Gut microbial adaptation to dietary consumption of fructose, artificial sweeteners and sugar alcohols: implications for host-microbe interactions contributing to obesity. Obes Rev 2012;13:799–809.
    1. Claesson MJ, Jeffery IB, Conde S, Power SE, O'Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O'Sullivan O, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178–84.

Source: PubMed

3
Abonnieren